Similarly, Drucker et al. reported the cost per patient for adjuvant and palliative treatment of trastuzumab per patient in HER2 + breast cancer was $49,000 and $28,000, respectively, and the acquisition cost of mAbs was found to be more than 94% (Drucker et al. 2008). The gene discussed is ERBB2; the disease is breast cancer.